The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Essential Roles of IL-6 Trans -Signaling in Colonic Epithelial Cells, Induced by the IL-6/Soluble–IL-6 Receptor Derived from Lamina Propria Macrophages, on the Development of Colitis-Associated Premalignant Cancer in a Murine Model
Abstract
Activation of the IL-6/Stat3 via IL-6 trans-signaling plays an important role in the pathogenesis of inflammatory bowel disease. Colitis-associated cancer (CAC) is a large bowel cancer and occurs with long-standing inflammatory bowel disease. The role of the IL-6/Stat3 in the development of CAC has not been fully understood. We investigate whether IL-6 trans-signaling contributes to the development of CAC using a mouse colitis-associated premalignant cancer (CApC) model. Chronic colitis (CC) was induced in BALB/c mice using dextran sodium sulfate. CApC was induced by dextran sodium sulfate treatment to CC-affected mice. IL-6 expression was determined by quantitative RT-PCR and immunofluorescence staining in colon. Phospho-Stat3 expression was examined by Western blotting and immunofluorescence analysis. The expression of IL-6 receptors (i.e., the IL-6R α-chain and gp130) and tumor necrosis factor-α converting enzyme in the colon was examined by laser-capture microdissection and immunofluorescence staining. Soluble IL-6Rα (sIL-6Rα) was examined by Western blotting of epithelial cell-depleted colonic tissues. We also investigated whether a soluble gp130-Fc fusion protein could prevent CApC. IL-6 expression was increased in the colon of CC- and CApC-affected mice and was restricted to lamina propria-macrophages. The expression of IL-6Rα and tumor necrosis factor-α converting enzyme was increased in the lamina propria CD11b-macrophages of CC-affected mice. sIL-6Rα expression was also increased in these tissues. Reduced levels of IL-6Rα generation were observed in the colonic epithelial cells of CC- and CApC-affected mice and were associated with the increased expression of gp130 and phospho-Stat3. Treatment with soluble gp130Fc significantly reduced the CApC. IL-6 trans-signaling in epithelial cells induced by macrophage-derived IL-6/sIL-6Rα plays a crucial role in the development of CAC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130
Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, K., Matsuda, T., Hirano, T., & Kishimoto, T. (1989) · Cell · doi:10.1016/0092-8674(89)90438-8 · Cited by 1,396
IL-6 is required for the development of Th1 cell-mediated murine colitis
Yamamoto, M., Yoshizaki, K., Kishimoto, T., & Ito, H. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.9.4878 · Cited by 411
Self-citationMatthews, V., Schuster, B., Schütze, S., Bussmeyer, I., Ludwig, A., Hundhausen, C., Sadowski, T., Saftig, P., Hartmann, D., Kallen, K.-J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210584200 · Cited by 390
Self-citation
Cited by
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212
Self-citationTargeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
Yu, H., Lee, H., Herrmann, A., Buettner, R., & Jove, R. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3818 · Cited by 2,137
Terzić, J., Grivennikov, S., Karin, E., & Karin, M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.058 · Cited by 1,974
Chronic inflammation and cytokines in the tumor microenvironment
Landskron, G., De la Fuente, M., Thuwajit, P., Thuwajit, C., & Hermoso, M. A. (2014) · Journal of Immunology Research · doi:10.1155/2014/149185 · Cited by 1,765
Rose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040
“Colon Cancer AOM/DSS model, DSS only model [78, 103]”
MethodSelf-citationInterleukin-6 Family Cytokines
Rose-John, S. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028415 · Cited by 799
Self-citationIL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis
Rokavec, M., Öner, M. G., Li, H., Jackstadt, R., Jiang, L., Lodygin, D., Kaller, M., Horst, D., Ziegler, P. K., Schwitalla, S., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73531 · Cited by 753
IL-6 and related cytokines as the critical lynchpins between inflammation and cancer
Taniguchi, K., & Karin, M. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.01.001 · Cited by 716
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
Jones, S. A., Scheller, J., & Rose-John, S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57158 · Cited by 683
Self-citationIL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer
Neurath, M. F., & Finotto, S. (2011) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2011.02.003 · Cited by 576
Liang, J., Nagahashi, M., Kim, E. Y., Harikumar, K. B., Yamada, A., Huang, W.-C., Hait, N. C., Allegood, J. C., Price, M. M., Avni, D., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.013 · Cited by 563
Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage
Grivennikov, S. I., & Karin, M. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.140145 · Cited by 560
Targeting IL-6 trans-signalling: past, present and future prospects
Rose-John, S., Jenkins, B. J., Garbers, C., Moll, J. M., & Scheller, J. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00856-y · Cited by 524
Self-citationInterleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update
Su, H., Lei, C.-T., & Zhang, C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00405 · Cited by 524
Interleukin-6: Biology, signaling and strategies of blockade
Schaper, F., & Rose-John, S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.07.004 · Cited by 509
Self-citationThe role of interleukin-6 signaling in nervous tissue
Rothaug, M., Becker-Pauly, C., & Rose-John, S. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.03.018 · Cited by 491
The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition
Garbers, C., Aparicio-Siegmund, S., & Rose-John, S. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.02.008 · Cited by 429
Self-citationPutoczki, T. L., Thiem, S., Loving, A., Busuttil, R. A., Wilson, N. J., Ziegler, P. K., Nguyen, P. M., Preaudet, A., Farid, R., Edwards, K. M., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.06.017 · Cited by 421
Epithelial–mesenchymal transition in colorectal cancer metastasis: A system review
Cao, H., Xu, E., Liu, H., Wan, L., & Lai, M. (2015) · Pathology - Research and Practice · doi:10.1016/j.prp.2015.05.010 · Cited by 356
Yao, D., Dong, M., Dai, C., & Wu, S. (2019) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izz149 · Cited by 338
IL-6 biology: implications for clinical targeting in rheumatic disease
Calabrese, L. H., & Rose-John, S. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.127 · Cited by 328
Self-citationInterleukin-6: from basic biology to selective blockade of pro-inflammatory activities
Scheller, J., Garbers, C., & Rose-John, S. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2013.11.002 · Cited by 308
Self-citationNew therapies for inflammatory bowel disease: from the bench to the bedside
Danese, S. (2012) · Gut · doi:10.1136/gutjnl-2011-300904 · Cited by 308
Blockade of IL-6 Trans Signaling Attenuates Pulmonary Fibrosis
Le, T.-T. T., Karmouty-Quintana, H., Melicoff, E., Le, T.-T. T., Weng, T., Chen, N.-Y., Pedroza, M., Zhou, Y., Davies, J., Philip, K., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302470 · Cited by 299
The soluble Interleukin 6 receptor: Generation and role in inflammation and cancer
Chalaris, A., Garbers, C., Rabe, B., Rose-John, S., & Scheller, J. (2011) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2010.10.007 · Cited by 289
Self-citationCytokines, IBD, and Colitis-associated Cancer
Francescone, R., Hou, V., & Grivennikov, S. I. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000236 · Cited by 272
IL-6 stimulates intestinal epithelial proliferation and repair after injury
Kuhn, K. A., Manieri, N. A., Liu, T.-C., & Stappenbeck, T. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114195 · Cited by 254
gp130 at the nexus of inflammation, autoimmunity, and cancer
Silver, J. S., & Hunter, C. A. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0410217 · Cited by 254
Barkhausen, T., Tschernig, T., Rosenstiel, P., van Griensven, M., Vonberg, R.-P., Dorsch, M., Mueller-Heine, A., Chalaris, A., Scheller, J., Rose-John, S., et al. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e318211ff56 · Cited by 169
Self-citationThe soluble interleukin 6 receptor: advanced therapeutic options in inflammation
Rose‐John, S. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.782 · Cited by 169
Self-citationAn IL-6 link between obesity and cancer
Ghosh, S. (2013) · Frontiers in Bioscience · doi:10.2741/e628 · Cited by 57
The Regenerative Activity of Interleukin-6
Galun, E., & Rose-John, S. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-308-4_4 · Cited by 34
Self-citation
Metadata
- Authors
- Matsumoto, S., Hara, T., Mitsuyama, K., Yamamoto, M., Tsuruta, O., Sata, M., Scheller, J., Rose-John, S., Kado, S.-I., & Takada, T.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-12-30
- Volume
- 184
- Issue
- 3
- Pages
- 1543-1551
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1904767156
- Cited by
- 211
- References
- 3
- FWCI
- 5.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.